The Massey Cancer Center is a matrix center located at Virginia Commonwealth University, whose mission is to provide comprehensive, cancer-focused basic, clinical, and population research, clinical services, outreach, and education to the State of Virginia and the nation. The major goals of the Cancer Center are 1) to facilitate high-quality basic, clinical, and population-based research focused on the cancer problem and 2) to promote interdisciplinary and transdisciplinary collaborations among the scientific programs and members of the Cancer Center and translate findings into more effective interventions for cancer prevention and treatment. During the last project period, NCI annual total cost funding for Cancer Center members increased from $15,777,576 to $18,011,992, and total peer-reviewed funding from $33,125,861 to $38,016,473. During this period we expanded translational and clinical research activities, increased high impact cancer-focused research, and increased transdisciplinary research. Major goals for the next grant period are to further enhance our translational-clinical research activities, increase the depth and scope of collaborative programmatic research, and intensify our research focus on the problems of health care disparities among racial, ethnic, and other underserved populations. Research activities of the Massey Cancer Center are earned out through five research programs: Cancer Cell Signaling, Cancer Molecular Genetics, Cancer Prevention and Control, Developmental Therapeutics, and Radiation Biology and Oncology. The translational programs include both basic research and either clinical/translational or applied population research so as to facilitate transdisciplinary collaboration and rapid implementation and dissemination of research findings. In order to provide support for the predominantly peer-reviewed research base of the scientific programs, the Cancer Center supports nine shared resources: Clinical Research;Biostatistics;Flow Cytometry;Biologic Macromolecule;Behavioral Measurement;Structural Biology;Transgenic/Knockout Mouse;Cancer Research Informatics and Services;and Tissue and Data Acquisition and Analysis. This application requests continuation of CCSG funding to provide partial support for these shared resources as well as for senior leadership, program leadership, administration, staff investigators, protocol-specific research, program planning and evaluation, protocol review and monitoring, data and safety monitoring, and developmental funds, which are necessary to facilitate and stimulate transdisciplinary cancer research and translation throughout the Cancer Center.

Public Health Relevance

The mission of MCC is to serve Virginia and the nation as an internationally recognized comprehensive research and treatment center dedicated to improving the quality of human life by eliminating suffering and death through development and delivery of more effective means for the detection, treatment, prevention, control and ultimate cure of cancer. The core of this mission is to facilitate interdisciplinary and transdisciplinary cancer research so as to harness the considerable intellectual talent and scientific resources of VCU and focus them on solving the nation's cancer problem.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016059-31S1
Application #
8546139
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ptak, Krzysztof
Project Start
1978-12-01
Project End
2017-04-30
Budget Start
2012-08-30
Budget End
2013-04-30
Support Year
31
Fiscal Year
2012
Total Cost
$76,207
Indirect Cost
$26,071
Name
Virginia Commonwealth University
Department
Biochemistry
Type
Schools of Medicine
DUNS #
105300446
City
Richmond
State
VA
Country
United States
Zip Code
23298
Booth, Laurence; Roberts, Jane L; Rais, Rumeesa et al. (2018) [Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration. Oncotarget 9:6062-6074
Floros, Konstantinos V; Lochmann, Timothy L; Hu, Bin et al. (2018) Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy. Proc Natl Acad Sci U S A 115:E2594-E2603
Warthan, Michelle D; Washington, Sonya L; Franzese, Samone E et al. (2018) The role of endoplasmic reticulum aminopeptidase 2 in modulating immune detection of choriocarcinoma. Biol Reprod 98:309-322
Lv, Dong-Wen; Zhang, Kun; Li, Renfeng (2018) Interferon regulatory factor 8 regulates caspase-1 expression to facilitate Epstein-Barr virus reactivation in response to B cell receptor stimulation and chemical induction. PLoS Pathog 14:e1006868
Rizzo, Juliana; Colombo, Ana C; Zamith-Miranda, Daniel et al. (2018) The putative flippase Apt1 is required for intracellular membrane architecture and biosynthesis of polysaccharide and lipids in Cryptococcus neoformans. Biochim Biophys Acta Mol Cell Res 1865:532-541
Brabec, Viktor; Kasparkova, Jana; Menon, Vijay et al. (2018) Polynuclear Platinum Complexes. Structural Diversity and DNA Binding. Met Ions Life Sci 18:
Liu, Runping; Li, Xiaojiaoyang; Huang, Zhiming et al. (2018) C/EBP homologous protein-induced loss of intestinal epithelial stemness contributes to bile duct ligation-induced cholestatic liver injury in mice. Hepatology 67:1441-1457
Moro, Kazuki; Kawaguchi, Tsutomu; Tsuchida, Junko et al. (2018) Ceramide species are elevated in human breast cancer and are associated with less aggressiveness. Oncotarget 9:19874-19890
Talukdar, Sarmistha; Pradhan, Anjan K; Bhoopathi, Praveen et al. (2018) MDA-9/Syntenin regulates protective autophagy in anoikis-resistant glioma stem cells. Proc Natl Acad Sci U S A 115:5768-5773
Luzi, Nicole M; Lyons, Charles E; Peterson, Darrell L et al. (2018) Kinetics and inhibition studies of the L205R mutant of cAMP-dependent protein kinase involved in Cushing's syndrome. FEBS Open Bio 8:606-613

Showing the most recent 10 out of 586 publications